DF6215 in Advanced Solid Tumors

What is the Purpose of this Study?

The purpose of this study is to determine the safety of an investigational drug called DF6215 in people who have a locally advanced or metastatic solid tumor. A locally advanced solid tumor is cancer that is confined to the area where it started but cannot be removed by surgery. A metastatic solid tumor is cancer that has spread from the place where it began to another part of the body. Researchers aim to evaluate the levels of DF6215 in the blood and safety of DF6215, as well as how people with certain types of solid tumor cancers respond to the drug. DF6215 will be given intravenously (via injection into the vein).


Eligibility

  • * Signed written informed consent
  • * Male or female patients aged ≥ 18 years
  • * Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 at study entry and an estimated life expectancy of at least 3 months
  • * Adequate hematological function
Show more

Where can I participate?

Cedars-Sinai Cancer at The Angeles Clinic and Research Institute : Saba Mukarram

More about this Clinical Trial

What is the full name of this clinical trial?

DF6215-001: A Phase 1/1B, First-in-human, Multi-Part, Open-Label study to investigate the safety tolerability, pharmacokinetics, biological and clinical activity of Df6215 in patients with advanced solid tumors

Study Details
Disease Type/Condition

Brain and Nervous System, Breast, Cervix, Colon, Lung, Other Female Genital, Ovary, Pancreas, Prostate

Principal Investigator

Hafez, Navid

Co-Investigators

Ani Balmanoukian, Cathie T Chung, Inderjit Mehmi, Justin Moyers, Kristopher Wentzel, Omid Hamid, Vi K. Chiu

Age Group

Adult

Phase

I/II

IRB Number

STUDY00003088

ClinicalTrials.gov ID

NCT06108479

Key Eligibility
ClinicalTrials.gov

How do I learn more about this study?
Name

Saba Mukarram

Phone
+1 310-231-2181
Email
MukarramS@cshs.org
Study Detail
Disease Type/Condition

Brain and Nervous System, Breast, Cervix, Colon, Lung, Other Female Genital, Ovary, Pancreas, Prostate

Principal Investigator

Hafez, Navid

Age Group

Adult

Phase

I/II

IRB Number

DF6215-001

ClinicalTrials.gov ID

NCT06108479

Key Eligibility
ClinicalTrials.gov

Contact
Name

Saba Mukarram

Phone
+1 310-231-2181
Email
MukarramS@cshs.org